According to Quotient's latest financial reports the company has a price-to-book ratio of -0.0064.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | -0.0064 | -99.7% |
2021-12-31 | -2.11 | -103.07% |
2020-12-31 | 68.7 | 62.5% |
2019-12-31 | 42.3 | 162.07% |
2018-12-31 | 16.1 | -72.67% |
2017-12-31 | 59.0 | -310.05% |
2016-12-31 | -28.1 | -318.81% |
2015-12-31 | 12.8 | -134.46% |
2014-12-31 | -37.3 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Atossa Therapeutics ATOS | 1.95 | -30,470.97% | ๐บ๐ธ USA |
Chembio Diagnostics CEMI | 0.9389 | -14,713.08% | ๐บ๐ธ USA |
Eterna Therapeutics ERNA | 4.34 | -67,599.79% | ๐บ๐ธ USA |